Literature DB >> 12774930

Persistent remission after immunosuppressive therapy of hairy cell leukemia mimicking aplastic anemia: two case reports.

Chiharu Sugimori1, Ken Kaito, Shinji Nakao.   

Abstract

Some patients with hairy cell leukemia (HCL) manifest pancytopenia and bone marrow hypoplasia without an apparent increase in atypical cells, so their disease resembles severe aplastic anemia at onset. We treated 2 HCL patients, who were initially diagnosed with aplastic anemia, with antithymocyte globulin (ATG) in combination with cyclosporine or antilymphocyte globulin (ALG). Both patients obtained partial remission in response to the immunosuppressive therapy and did not need transfusion treatment for more than 3 years. Sustained improvement of hematopoiesis in such B-cell malignancies after ATG/ ALG therapy suggests that the mechanisms underlying successful immunosuppressive therapy for aplastic anemia may involve B-cell suppression, inhibiting hematopoietic stem cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12774930     DOI: 10.1007/bf02982650

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  11 in total

1.  Antilymphocyte globulin, cyclosporine, prednisolone, and granulocyte colony-stimulating factor for severe aplastic anemia: an update of the GITMO/EBMT study on 100 patients. European Group for Blood and Marrow Transplantation (EBMT) Working Party on Severe Aplastic Anemia and the Gruppo Italiano Trapianti di Midolio Osseo (GITMO).

Authors:  A Bacigalupo; B Bruno; P Saracco; E Di Bona; A Locasciulli; F Locatelli; A Gabbas; C Dufour; W Arcese; G Testi; G Broccia; M Carotenuto; P Coser; T Barbui; P Leoni; A Ferster
Journal:  Blood       Date:  2000-03-15       Impact factor: 22.113

2.  Prognostic significance of immunoglobulin heavy chain gene rearrangement in patients with acute myelogenous leukemia.

Authors:  K Kyoda; S Nakamura; S Matano; S Ohtake; T Matsuda
Journal:  Leukemia       Date:  1997-06       Impact factor: 11.528

3.  Cyclosporin A for the treatment of cytopenia associated with chronic lymphocytic leukemia.

Authors:  J Cortes; S O'Brien; J Loscertales; H Kantarjian; F Giles; D Thomas; C Koller; M Keating
Journal:  Cancer       Date:  2001-10-15       Impact factor: 6.860

4.  Development, production and quality control of clinically applied antilymphocyte globulin.

Authors:  F R Seiler
Journal:  Postgrad Med J       Date:  1976       Impact factor: 2.401

5.  Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia.

Authors:  H Hagberg; L Lundholm
Journal:  Br J Haematol       Date:  2001-12       Impact factor: 6.998

6.  Effects of antithymocyte globulin on bone marrow CD34+ cells in aplastic anaemia and myelodysplasia.

Authors:  S B Killick; J C Marsh; E C Gordon-Smith; L Sorlin; F M Gibson
Journal:  Br J Haematol       Date:  2000-03       Impact factor: 6.998

7.  Serum soluble interleukin-2 receptor is associated with clinical and pathologic disease status in hairy cell leukemia.

Authors:  J M Richards; R Mick; J M Latta; K Daly; M J Ratain; J W Vardiman; H M Golomb
Journal:  Blood       Date:  1990-11-15       Impact factor: 22.113

8.  Intensive immunosuppression with antithymocyte globulin and cyclosporine as treatment for severe acquired aplastic anemia.

Authors:  S J Rosenfeld; J Kimball; D Vining; N S Young
Journal:  Blood       Date:  1995-06-01       Impact factor: 22.113

Review 9.  Treatment of hairy-cell leukemia: current views.

Authors:  M S Tallman; L C Peterson; D Hakimian; S Gillis; A Polliack
Journal:  Semin Hematol       Date:  1999-04       Impact factor: 3.851

Review 10.  Clinical problems in hairy cell leukemia: diagnosis and management.

Authors:  C A Westbrook; D W Golde
Journal:  Semin Oncol       Date:  1984-12       Impact factor: 4.929

View more
  1 in total

1.  Hairy cell leukemia responsive to anti-thymocyte globulin used as immunosuppressive therapy for aplastic anemia.

Authors:  Shiho Fujiwara; Hirosada Miyake; Kisato Nosaka; Minoru Yoshida; Sonoko Ishihara; Kentaro Horikawa; Yuji Yonemura; Kenichi Iyama; Hiroaki Mitsuya; Norio Asou
Journal:  Int J Hematol       Date:  2009-10-14       Impact factor: 2.490

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.